Answers are grounded in this paper and cite their sources.
Drug-resistant tuberculosis (TB) is a major global health challenge. This retrospective, laboratory-based study aimed to describe the antimicrobial susceptibility profile of Mycobacterium tuberculosis complex isolates in the Dominican Republic and to assess factors associated with antimicrobial resistance. All culture-confirmed clinical M. tuberculosis complex isolates processed in a private referral microbiology laboratory from 2021 to 2025 were included. Drug susceptibility testing was performed according to CLSI M62 recommendations. A total of 184 patients were included. Median age was 38 years (interquartile range 28–50), and 70.7% of isolates were obtained from pulmonary specimens. Overall, 136 isolates (73.9%) were susceptible to all tested drugs, whereas 48 (26.1%) were resistant to at least one drug. The most frequent resistance was to isoniazid (n = 29; 15.8%) and streptomycin (n = 27; 14.7%), followed by rifampicin (n = 11; 6.0%). Pyrazinamide resistance was uncommon (n = 4; 2.2%), and no resistance was detected to ethambutol, second-line injectable agents, or fluoroquinolones. Among the 11 rifampicin-resistant isolates, three (1.6% of all isolates) were rifampicin-resistant without concomitant isoniazid resistance, whereas eight (4.3%) were multidrug-resistant (MDR-TB). In conclusion, more than one-quarter of isolates were resistant to at least one anti-TB drug, most commonly isoniazid and streptomycin. Overall rifampicin resistance, including MDR-TB, was detected in 6.0% of isolates. These findings highlight the need to strengthen drug resistance surveillance and expand access to rapid molecular and phenotypic drug susceptibility testing to guide appropriate treatment and support TB control strategies in the Dominican Republic.
No takes yet. Share an insight, caveat, or question.
Perez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: